medivet update, page-7

Stayer,

The main competitors to Medivet in the US are Vet-Stem and Stemlogix. The main competitive advantage Medivet has over each is -
(1) Vet-Stem: Requires the fat tissue sample to be sent offsite for processing. Medivet allows it to be done in-house at the clinic
(2) Stemlogix: Allows the treatment to be done in-house just like Medivet, however they don't perform stem-cell activation like Medivet does

According to the Stemlogix site stem-cell activation is not needed. This seems aimed directly at Medivet and the Adistem light activation technology. So it would seem that the Medivet technology would still work without the activation process, but wouldn't be as effective -
http://www.stemlogix.com/site/sctf.htm

Medivet and Adistem established their relationship during both company's formative years. They both have strong Australian roots and hopefully we're safe in thinking the relationship with Adistem and the future prospects would have been one of the key items of due diligence conducted.

I'm sure we're not the only ones that see great potential that hasn't been realised. After a small loss in FY2011, FY2012 and FY2013 had disappointing bottom line results, notwithstanding the tough trading conditions.

They have now had two consecutive quarters of positive cashflow. It's not something that was ever achieved as BMDi and the first time as Medical Australia. Hopefully it's an early pointer of better things to come....